Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 10:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 415 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Cream Clear all
Completed Phase 3 Interventional Results available

Safety and Effectiveness Study of Imiquimod Creams for the Treatment of Actinic Keratoses (AKs)

NCT00603798
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Imiquimod cream, Placebo cream
Drug
Lead sponsor
Graceway Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
490 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
26
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Encino, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2010 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of SST 0225, a Topical Ibuprofen Cream, in the Treatment of Pain Associated With Acute Ankle Sprain

NCT01874626
View directory record Official record
Conditions
Acute Ankle Sprain
Interventions
Placebo, SST-0225 Topical Ibuprofen Cream
Drug
Lead sponsor
Strategic Science & Technologies, LLC
Industry
Eligibility
16 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Guilford, Connecticut
Source: ClinicalTrials.gov public record
Updated May 21, 2021 · Synced Oct 19, 2026, 10:15 AM EDT
Not listed Phase 2 Interventional

Study to Compare Efficacy of Topical ARYS-01 (Sorivudine) Cream 3%, Oral Valaciclovir and Combination ARYS-01 Cream 3%/Oral Valaciclovir for Treatment of Herpes Zoster (Shingles)

NCT00652184
View directory record Official record
Conditions
Herpes Zoster, Postherpetic Neuralgia
Interventions
ARYS-01 (sorivudine) cream 3% or placebo cream, placebo, valaciclovir
Drug
Lead sponsor
aRigen Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
10
States / cities
Beverly Hills, California • Encino, California • Vista, California + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2008 · Synced Oct 19, 2026, 10:15 AM EDT
Not yet recruiting Phase 2 Interventional

Rapamycin Dose-Ranging Efficacy Study in Port Wine Stains

NCT07436611
View directory record Official record
Conditions
Port Wine Stains
Interventions
Rapamycin cream, Pulsed dyed laser
Drug · Procedure
Lead sponsor
AFT Pharmaceuticals, Ltd.
Industry
Eligibility
Up to 10 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Corpus Christi, Texas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 2 Interventional Results available

Personalized Treatment Algorithms for Difficult-to-treat Asthma

NCT04179461
View directory record Official record
Conditions
Asthma in Children
Interventions
Cholecalciferol, antihistamine, Azithromycin, emollient cream, Fluticasone Propionate, Asthma Controller Medication
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 17 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 20, 2021 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 4 Interventional Results available

CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial

NCT00847912
View directory record Official record
Conditions
Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Skin Neoplasms, Skin Diseases, Neoplasms, Basal Cell, Neoplasms, Squamous Cell, Carcinoma
Interventions
5-fluorouracil, Placebo, vehicle control
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
954 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
13
States / cities
Palo Alto, California • San Diego, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus

NCT05593432
View directory record Official record
Conditions
Cutaneous Lichen Planus
Interventions
Ruxolitinib cream, Vehicle cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2024 · Synced Oct 19, 2026, 10:15 AM EDT
Not listed Not applicable Interventional

Topical Collagen-Silver Versus Standard Care Following Removal of Ingrown Nails

NCT00641433
View directory record Official record
Conditions
Ingrown Nail
Interventions
oxidized regenerated cellulose collagen-silver, topical silver sulfadiazine cream
Device · Drug
Lead sponsor
Rosalind Franklin University of Medicine and Science
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
North Chicago, Illinois • Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 24, 2008 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (25)

NCT02608450
View directory record Official record
Conditions
Acne Vulgaris
Interventions
CB-03-01 cream, 1%, Vehicle cream
Drug
Lead sponsor
Cassiopea SpA
Industry
Eligibility
9 Years and older
Enrollment
708 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
44
States / cities
Little Rock, Arkansas • Fremont, California • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2020 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study of Treatments Used for White Spot Lesions After Orthodontic Treatment.

NCT01059058
View directory record Official record
Conditions
Tooth Demineralization
Interventions
MI Paste Plus, PreviDent Fluoride Varnish, Normal Home Care
Procedure
Lead sponsor
University of Washington
Other
Eligibility
12 Years to 20 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 17, 2015 · Synced Oct 19, 2026, 10:15 AM EDT
Terminated Phase 2 Interventional

Efficacy and Safety of Product S2G6T-1in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis

NCT02842021
View directory record Official record
Conditions
Tinea Pedis
Interventions
S2G6T-1, S2G6T-2, S2G6T-3, S2G6T-4
Drug
Lead sponsor
Sol-Gel Technologies, Ltd.
Industry
Eligibility
12 Years and older
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
19
States / cities
San Diego, California • Clearwater, Florida • North Miami Beach, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Oct 19, 2026, 10:15 AM EDT
Recruiting Not applicable Interventional

Pilot Trial Assessing the Effectiveness of Laser Hair Depilation on Pilonidal Disease Recurrence in Patients With Darker Skin Color

NCT06406621
View directory record Official record
Conditions
Pilonidal Disease
Interventions
Laser hair depilation, Standard of Care (SOC)
Procedure · Other
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
10 Years to 21 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa

NCT05635838
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Ruxolitinib cream, Vehicle cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
15
States / cities
Phoenix, Arizona • Fountain Valley, California • Boca Raton, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2024 · Synced Oct 19, 2026, 10:15 AM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Photodynamic Therapy and Microvesicles

NCT03960125
View directory record Official record
Conditions
Photodynamic Therapy, Microvesicle Particle
Interventions
Photodynamic Therapy, 4% Imipramine, Base Cream
Device · Drug
Lead sponsor
Wright State University
Other
Eligibility
21 Years to 45 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Fairborn, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 3 Interventional

S-Caine™ Peel (Skin Numbing Cream) to Treat Pain During Vascular Access Procedures in Children

NCT00125255
View directory record Official record
Conditions
Pain
Interventions
S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%), Placebo Peel
Drug
Lead sponsor
ZARS Pharma Inc.
Industry
Eligibility
5 Years to 17 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Equivalence of Estradiol Vaginal Cream 0.01% to Estrace® Cream 0.01% in Atrophic Vaginitis

NCT03294538
View directory record Official record
Conditions
Atrophic Vaginitis
Interventions
Generic Estradiol Vaginal Cream USP, 0.01%, Estrace® Vaginal Cream USP, 0.01%, Vehicle Vaginal Cream
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
30 Years to 75 Years · Female only
Enrollment
663 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
44
States / cities
Tucson, Arizona • La Mesa, California • Sacramento, California + 33 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Effect of a Nu Skin Product and Device for Brown Spots

NCT01149876
View directory record Official record
Conditions
Hyperpigmentation
Interventions
Nu Skin Product, Cosmetic instrument, Tretinoin cream 0.05, CeraVe moisturizer
Other · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
25 Years to 55 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 6, 2014 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

A Multi-center, Double-blind, Randomized Study, Comparing Clindamycin Phosphate Vaginal Cream 2% (Watson Laboratories, Inc.) to Clindesse® (Ther-Rx™, Clindamyin Phosphate Vaginal Cream 2%) and Both Active Treatments to a Placebo Control in the Treatment of Bacterial Vaginosis in Non-pregnant Women

NCT02210689
View directory record Official record
Conditions
BACTERIAL VAGINOSIS, Signs and Symptoms to be Evaluated and Recorded Include, Vaginal Discharge Color, Odor, and Consistency, Vulvovaginal Itching and Irritation (Subjective) Absent, Mild, Moderate, or Severe, Vulvovaginal Inflammation (Objective) Absent, Mild, Moderate, or Severe
Interventions
clindamycin phosphate vaginal cream 2%, placebo
Drug · Other
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
15
States / cities
Birmingham, Alabama • La Mesa, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Oct 19, 2026, 10:15 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

NCT03568318
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Placebo, Upadacitinib, Topical corticosteroids (TCS)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
12 Years to 75 Years
Enrollment
1,533 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
59
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 19, 2026, 10:15 AM EDT
Terminated Phase 3 Interventional

Evaluate the Safety and Efficacy of ON101 Cream for the Treatment of Chronic Diabetic Foot Ulcers

NCT04962139
View directory record Official record
Conditions
Chronic Diabetic Foot Ulcers
Interventions
ON101 Cream, Vehicle Cream
Drug · Other
Lead sponsor
Oneness Biotech Co., Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
14
States / cities
Mesa, Arizona • Carlsbad, California • Castro Valley, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)

NCT03345914
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Dupilumab, Matching Placebo, Background Treatment: Topical Corticosteroids, Background Treatment: Moisturizers
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
6 Years to 11 Years
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
31
States / cities
Birmingham, Alabama • Gilbert, Arizona • Bakersfield, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 1 Interventional Results available

Bioequivalence Study of Two Imiquimod Cream 5%

NCT00828568
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Imiquimod 5% manufactured by Taro, Aldara - Imiquimod 5%, Imiquimod Vehicle manufactured by Taro
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
20
States / cities
Gilbert, Arizona • Tempe, Arizona • Tuscon, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2014 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Vaginal Estrogen on Postpartum Atrophy, Perineal Pain, and Sexual Function

NCT03493126
View directory record Official record
Conditions
Vaginal Atrophy
Interventions
Estradiol, Placebo
Drug · Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 22, 2021 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 3 Interventional

BE Study of Naftifine HCL

NCT02633813
View directory record Official record
Conditions
Tinea Pedis
Interventions
Naftifine hydrochloride 2%, Placebo, Naftin® 2% (Naftifine hydrochloride 2%)
Drug
Lead sponsor
Genzum Life Sciences
Industry
Eligibility
18 Years and older
Enrollment
693 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
12
States / cities
Brandon, Florida • Miami, Florida • Miramar, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Oct 19, 2026, 10:15 AM EDT